Damir Illich

Using microbes to drug the undruggable

Crescent Enterprises is a leading multinational company growing diversified global businesses that are sustainable, scalable, and profitable. Headquartered in the United Arab Emirates, with business operations in 15 countries, it operates under four enterprise platforms: - CE-Operates, with subsidiaries and affiliates in the infrastructure sector - CE-Invests, a balanced portfolio of alternative asset class investments, including private equity, real estate and other structured investments - CE-Ventures, a corporate venture capital platform that makes strategic investments in early- to late stage high-growth companies and select venture funds globally - CE-Creates, an internal business incubator, building start-ups that are socially-conscious and financially feasible Crescent Enterprises employees over 1,800 people and operates with a philosophy that embraces corporate governance, inclusive growth, and responsible business practices. A subsidiary of the Crescent Group, one of the most progressive family business groups that have been actively contributing to the economic landscape of the Middle East and North Africa (MENA) region for over 47 years. Crescent Group’s other subsidiary, Crescent Petroleum, is the first and the largest indigenous, privately owned upstream oil and gas company in the Middle East.

Araris Biotech AG is pioneering a novel linker technology for antibody-drug conjugates (ADCs.) Our linker platform enables the attachment of any payload to ‘off the shelf’ antibodies without the need of prior antibody engineering.

With offices in Seattle, Wash., and Irvine, Calif., Visus Therapeutics is a clinical-stage pharmaceutical company focused on developing innovative ophthalmic therapies to improve vision for people around the world. The company is developing novel miotic formulations for a once-daily eye drop to correct the loss of near vision associated with presbyopia. In parallel, Visus Therapeutics is focused on advancing its pipeline of early-stage ophthalmic product candidates with applications in ocular surface disease, glaucoma and age-related macular degeneration. Additionally, Visus Therapeutics has entered into a worldwide exclusive licensing agreement with DelSiTech Ltd, a leader in advanced, biodegradable, silica-based, controlled-release materials, to develop novel drug delivery technology that can help optimize the clinical benefit of ophthalmic therapies.

Our collaborators and partners are driven by a desire to contribute to the development of new ways of fighting cancer. The therapies developed by NETRIS Pharma are based on cellular mechanisms identified by a world-renowned research group. Located in Léon Bérard Cancer Center (Lyon, France), NETRIS Pharma is a unique model of a biotechnology company integrated within a comprehensive cancer center.

Using microbes to drug the undruggable

Crescent Enterprises is a leading multinational company growing diversified global businesses that are sustainable, scalable, and profitable. Headquartered in the United Arab Emirates, with business operations in 15 countries, it operates under four enterprise platforms: - CE-Operates, with subsidiaries and affiliates in the infrastructure sector - CE-Invests, a balanced portfolio of alternative asset class investments, including private equity, real estate and other structured investments - CE-Ventures, a corporate venture capital platform that makes strategic investments in early- to late stage high-growth companies and select venture funds globally - CE-Creates, an internal business incubator, building start-ups that are socially-conscious and financially feasible Crescent Enterprises employees over 1,800 people and operates with a philosophy that embraces corporate governance, inclusive growth, and responsible business practices. A subsidiary of the Crescent Group, one of the most progressive family business groups that have been actively contributing to the economic landscape of the Middle East and North Africa (MENA) region for over 47 years. Crescent Group’s other subsidiary, Crescent Petroleum, is the first and the largest indigenous, privately owned upstream oil and gas company in the Middle East.

IQVIA (NYSE:IQV) is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. IQVIA’s portfolio of solutions are powered by IQVIA Connected Intelligence™ to deliver actionable insights and services built on high-quality health data, Healthcare-grade AI™, advanced analytics, the latest technologies and extensive domain expertise. With approximately 88,000 employees in over 100 countries, including experts in healthcare, life sciences, data science, technology and operational excellence, IQVIA is dedicated to accelerating the development and commercialization of innovative medical treatments to help improve patient outcomes and population health worldwide. IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific progress, in an effort to advance healthcare. To learn more, visit www.iqvia.com.

Araris Biotech AG is pioneering a novel linker technology for antibody-drug conjugates (ADCs.) Our linker platform enables the attachment of any payload to ‘off the shelf’ antibodies without the need of prior antibody engineering.

With offices in Seattle, Wash., and Irvine, Calif., Visus Therapeutics is a clinical-stage pharmaceutical company focused on developing innovative ophthalmic therapies to improve vision for people around the world. The company is developing novel miotic formulations for a once-daily eye drop to correct the loss of near vision associated with presbyopia. In parallel, Visus Therapeutics is focused on advancing its pipeline of early-stage ophthalmic product candidates with applications in ocular surface disease, glaucoma and age-related macular degeneration. Additionally, Visus Therapeutics has entered into a worldwide exclusive licensing agreement with DelSiTech Ltd, a leader in advanced, biodegradable, silica-based, controlled-release materials, to develop novel drug delivery technology that can help optimize the clinical benefit of ophthalmic therapies.